Amylyx Pharmaceuticals company information, Employees & Contact Information

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis Yahoo Finance

Clinical Trial Setback: Amylyx's AMX0035 Shows No Benefit in Progressive Supranuclear Palsy Study Stock Titan

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 The AI Journal

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results Business Wire

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 FinancialContent

Post-Bariatric Hypoglycemia (PBH) Amylyx

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer citybiz

Amylyx (AMLX) Sets Stage for Major Strategic Updates at Premier Healthcare Conference Stock Titan

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire

Careers Amylyx

Amylyx Pharmaceuticals Discontinues AMX0035 After Failing Primary End Point in Phase 3 PHOENIX Trial NeurologyLive

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock Business Wire

Wolfram Syndrome Amylyx

Amylyx Mulls Over Pulling AMX0035 Following Disappointing Phase 3 PHOENIX Findings NeurologyLive

Leadership Amylyx

James Frates Joins Amylyx Pharmaceuticals as Chief Financial Officer Amylyx

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome Business Wire

Paul Fonteyne Joins Amylyx Pharmaceuticals Board of Directors Amylyx

About PSP and how it manifests Amylyx

AMX0035 Continues to Stabilize and Improve Wolfram Syndrome at 48 Weeks, Phase 2 HELIOS Trial Shows NeurologyLive

Amylyx axes rare disease program after Relyvrio fails to beat placebo Fierce Biotech

Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer citybiz

Amylyx culls rare neurological disorder programme after trial failure Pharmaceutical Technology

Amylyx to pull ALS drug from market, cut 70% of staff statnews.com

Amylyx Pharmaceuticals Appoints Gina M. Mazzariello as Chief Legal Officer citybiz

After Amylyx ALS trial failure, patients share disappointment and fear — but some hope statnews.com

FDA gives Amylyx green light for phase 1 ALS trial after clinical hold Fierce Biotech

After withdrawing ALS drug, Amylyx CEOs take lessons to rebuild the pipeline Fierce Biotech

Investigational oral therapy improves pancreatic function, symptoms in Wolfram syndrome Healio

Amylyx Voluntarily Discontinues ALS Treatment Relyvrio Following Phase 3 Trial Results Pharmacy Times

The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals Partner on Real-World Evidence Generation for a Novel Investigational Therapy in ALS with the Goal of Advancing Health Outcomes for Canadians Living with ALS Business Wire

After trial failure, will Amylyx pull ALS drug Relyvrio off the market? Fierce Pharma

Amylyx Pivots to GLP-1 Space, Acquires Phase III-Ready Asset from Eiger BioSpace

AMX0035 Approved for the Treatment of ALS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights NeurologyLive

Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023 FinancialContent

AMX0035 Approved! How We Got Here and What Comes Next The ALS Association

Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference FinancialContent

AMLX Stock Price and Chart — NASDAQ:AMLX TradingView

Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis MarketBeat

FDA Advisors Narrowly Oppose Amylyx’s ALS Drug Barron's

Hundreds attend Denver Walk to Defeat ALS, many hopeful about new treatment Denver7

The ALS Association and ALS Finding a Cure Announce Joint Funding Support for Amylyx Clinical Trial of AMX0035 for the Treatment of ALS PR Newswire

FDA approves Relyvrio as new treatment option for ALS Medical Dialogues